HTHongjun Tang

Hongjun Tang

*This is an algorithmically generated author record based on publicly available information.

Hongjun Tang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Dongbing Li

    Molecular Genetics Laboratory, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou 215128, China

    2 shared publications
  • Jiangtao He

    Department of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China

    2 shared publications
  • Jingsheng Chen

    Department of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China

    2 shared publications
  • Kangwei Jiang

    Medical Department, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China

    2 shared publications
  • Fangming Tang

    Department of Cardiology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China

    1 shared publication
  • Haiming Zhong

    Department of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital, Zhanjiang, 524002, Guangdong, People’s Republic of China

    1 shared publication

Latest Publications

  • Unraveling the Resistance: Challenges and Advances in PARP Inhibitor Therapy for BRCA1/2 Breast Cancer

    by Hongjun Tang, Jingsheng Chen, Kangwei Jiang, Jiangtao He, Fangming Tang, Dongbing Li, Yuye Wu

    Breast cancer is the most prevalent malignant tumor among women globally, with breast cancer susceptibility genes (BRCA1 and BRCA2, BRCA1/2) mutations significantly increasing the risk of developing aggressive forms of the disease. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have shown promise in treating BRCA1/2-mutated breast cancer by exploiting deficiencies in homologous recombination (HR) repair. However, the emergence of acquired resistance poses a significant challenge. Our study examines the mechanisms of PARPi resistance in BRCA1/2-mutated breast cancer, synthesizing recent clinical advancements and identifying key resistance pathways, including HR recovery, DNA replication fork stability, and epigenetic modifications. We also highlight potential strategies to overcome these challenges to PARPi resistance, such as combination therapies and novel targets. Our comprehensive analysis aims to inform future clinical practices and guide the development of more effective treatment strategies.


  • Open Access

    Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of OVOLs in Breast Cancer

    by Jingsheng Chen, Hongjun Tang, Taidong Li, Kangwei Jiang, Haiming Zhong, Yuye Wu, Jiangtao He, Dongbing Li, Mengzhen Li, Xingsheng Cai

    Background: The study aimed to investigate the expression of OVOLs in breast cancer (BRCA) tissues and their value in prognosis. Methods: ONCOMINE was used to analyze the expressions of OVOL1, OVOL2, and OVOL3 mRNA between BRCA tissues and normal breast tissues. The Wilcoxon rank sum test and t-test were used to assess the expression of OVOLs between BRCA tissues and unpaired/paired normal breast tissues. GEPIA and ROC curves were used to analyze the relationship between OVOLs expression and clinical pathological stage. Kaplan–Meier plotter was used to analyze prognosis. cBioPortal was used to analyze the mutation of OVOLs. GEPIA was used to analyze the co-expression of OVOLs. GO and KEGG analyses were performed by the DAVID software to predict the function of OVOLs co-expression genes. Results: The expression of OVOL1/2 was significantly higher in BRCA tissues than in normal breast tissues. The OVOL3 expression correlated with tumor stage. The AUC of OVOLs was 0.757, 0.754, and 0.537, respectively. OVOL1 high expression was associated with shorter overall survival (HR: 1.48; 95% CI: 1.07– 2.04; P=0.018). The OVOLs were associated with pathways including axon guidance, thyroid hormone signaling pathway, and ubiquinone and other terpenoid-quinone biosynthesis. Conclusion: OVOL1 is a new potential marker of prognosis in BRCA, and OVOL1/2 are potential therapeutic targets in BRCA.